Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug for sight-robbing disease ... iron-based phosphate binder AP301 ...

At present, it is unknown which cells in the damaged organ are responsible for increased erythropoietin production in a hydronephrotic kidney. In patients with cystic renal diseases (in whom mild ...

Serum phosphorus concentrations are seldom less than 2.0 mg/dl (0.6 mmol/1) unless patients' phosphorus intake is low or they simultaneously ingest phosphate-binding antacids. [34] Severe ...

The recipient, a 30-year-old woman from Shirdi, had been suffering from end-stage kidney disease due to diabetes and had been on dialysis since 2022. Initially misdiagnosed as having ‘O’ blood group, ...